Interventional device firm Boston Scientific of Natick, MA, reported that it has received indication extensions to the European CE Mark for its Taxus Liberté paclitaxel-eluting coronary stent system.
In addition to its existing indication for the treatment of de-novo lesions in native coronary arteries, the product is now indicated in Europe for the treatment of restenotic lesions and total occlusions in patients with coronary artery disease, including acute myocardial infarction, the company said.
Boston Scientific also received the CE Mark for a large-vessel-diameter version of Taxus Liberté. The device uses a modified cell design intended for drug delivery in larger vessels, and will be available in a 4-mm diameter and seven different lengths, according to the firm.
By AuntMinnie.com staff writers
May 16, 2006
Related Reading
Boston Scientific, J&J get mixed ruling on stent disputes, May 12, 2006
Boston Scientific names Baim as chief medical officer, May 11, 2006
Boston Scientific closes Guidant purchase, April 24, 2006
Boston Scientific, Abbott receive FTC OK on Guidant, April 20, 2006
Boston Scientific sets Q1 sales record, April 18, 2006
Copyright © 2006 AuntMinnie.com
